NuCana plc
NUC-7738
melanoma
Resolved
97days ago
FDA decision · Apr 1, 2026
What's at stake
The FDA's approval decision on NUC-7738 for melanoma is due Apr 1, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 13h ago
“The U.S. Food and Drug Administration (the “FDA”) cleared our Investigational New Drug application (“IND”) for NUC-7738 in April 2026.”